Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1597 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
Jürgen Braun¹, Bjoern Buehring¹, Xenofon Baraliakos¹, Lianne S. Gensler², Brian Porter³, Abhijit Shete⁴, Erhard Quebe-Fehling⁵ and Sibylle Haemmerle⁵, ¹Ruhr-University Bochum, Herne, Germany, ²University of California, San Francisco, CA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Low bone mass is common in ankylosing spondylitis (AS) and patients (pts) with AS have an increased risk of bone fracture.1-3 Treatment of AS…
Abstract Number: 2215 • 2018 ACR/ARHP Annual Meeting
Evaluation of Left Ventricular Systolic and Diastolic Myocardial Function in Patients with Ankylosing Spondylitis By Speckle-Tracking Echocardiography
Hang Yang¹, Yi Zhao¹, Yujia Liang², Wenkai Yan³, Yi Liu⁴, Lingshu Zhang¹ and Tony Marion⁵, ¹Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China, ²Department of Cardiology, West China Hospital, Sichuan University, CHENGDU, China, ³Southern Medical University, GUANGZHOU, China, ⁴Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, ⁵Immunology and Biochemistry University of Tennessee Health Science Center, Memphis, TN
Background/Purpose: Patients with ankylosing spondylitis (AS) are at increased risk for cardiovascular disease (CVD), although strategies to detect subclinical CVD are poorly characterized. The aim…
Abstract Number: 276 • 2018 ACR/ARHP Annual Meeting
Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study
S. Hoekstra¹, Tamara Rusman², Michael T. Nurmohamed³, Christiaan van Denderen⁴ and Irene van der Horst-Bruinsma⁵, ¹Rheumatology, VU Univeresity Medical Center, Amsterdam, Netherlands, ²Rheumatology, VU University medical centre, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Despite several observations of gender differences in TNF inhibitor (TNFi) treatment response and adherence in ankylosing spondylitis (AS) patients, limited studies were conducted. Our…
Abstract Number: 689 • 2018 ACR/ARHP Annual Meeting
Association of Kinesiophobia, Aerobic Exercise, Functional Impairment and Disease Activity of Patients with Rheumatoid Arthritis and Spondyloarthritis
Daniele Peres¹, Nicolas Tordi², Daniel Wendling³, Yoshimasa Sagawa⁴ and Clément Prati⁵, ¹EA 4267 PEPITE (FHU INCREASE) – Plateforme EPSI, Université de Bourgogne Franche-Comté, Besançon,, France, ²PEPITE EA 4267, Bourgogne Franche-Comté University, Besançon, France, ³Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁴Laboratoire de l'Exploration Fonctionnelle et Clinique du Mouvement (LEFCM), BESANCON, France, ⁵Rheumatology, University Hospital - Bourgogne Franche Comté University, Besancon, France
Association of kinesiophobia, aerobic exercise, functional impairment and disease activity of patients with rheumatoid arthritis and spondyloarthritis.Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SA) are the…
Abstract Number: 1603 • 2018 ACR/ARHP Annual Meeting
Gender-Specific Differences in Chinese Patients with Ankylosing Spondylitis
Weiping Kong¹, Caroline Jefferies², Thomas Learch³, Xiaowei Gan¹, Jinrui Cui⁴, Yuan Xu¹, Dier Jin¹, Yingze Zhang¹, Jianming Wang¹, Qingwen Tao¹, Xiaoping Yan¹, Michael Weisman⁵ and Mariko Ishimori⁶, ¹China-Japan Friendship Hospital, Beijing, China, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Radiology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Harbor UCLA Medical Center, Los Angeles, CA, ⁶Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Growing evidence suggests gender-specific differences in the phenotypes of ankylosing spondylitis (AS). However, a literature search failed to reveal evidence of such differences in…
Abstract Number: 2377 • 2018 ACR/ARHP Annual Meeting
Body Image in Rheumatic Diseases: A Systematic Review
Shadi Gholizadeh¹, Annie Meier², Sarah D. Mills³ and Vanessa L. Malcarne⁴, ¹Clinical Psychology, SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²Psychology, San Diego State University, San Diego, CA, ³Medicine, Lineberger Comprehensive Cancer Center University of North Carolina, Durham, NC, ⁴SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA
Background/Purpose: In health conditions that cause changes in appearance, especially in areas of the body that are highly visible and socially salient (e.g., face and…
Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Jürgen Braun¹, Xenofon Baraliakos¹, Atul A. Deodhar², Denis Poddubnyy³, Paul Emery⁴, Evie Maria Delicha⁵, Zsolt Talloczy⁶ and Brian Porter⁶, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…
Abstract Number: 1473 • 2017 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In Germany no prospective data are available for Golimumab (GLM) in patients with RA, AS and PsAregarding outcomes evaluating work productivity and activity in…
Abstract Number: 1546 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
Walter P. Maksymowych¹, Ernest Choy², Yusuf Yazici³, Jessica A. Walsh⁴, Howard Thom⁵, Chrysostomos Kalyvas⁶, Todd Fox⁷, Kunal Gandhi⁸ and Steffen Jugl⁷, ¹Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ²Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ³School of Medicine, New York University School of Medicine, New York City, NY, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, ⁶Real World Strategy and Analytics, MAPI Group, Houten, Netherlands, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: No data are available from head-to-head randomized controlled trials (RCTs) between secukinumab 150mg (SEC; an anti-IL-17A) and golimumab 50mg (GOL; a TNF inhibitor [TNFi])…
Abstract Number: 2506 • 2017 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis/Axial Spondyloarthritis Smoking Is Associated with a Dose Related Elevation in CRP, Worse Disease Activity and Worse Quality of Life over One Year
Simon Stebbings¹, Mary Wallace², Andrew A. Harrison³, Nicola Dalbeth⁴, Douglas White⁵, Lisa K. Stamp⁶, Daniel Ching⁷ and John Highton⁸, ¹Dunedin Hospital, Department of Rheumatology, Dunedin, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Rheumatology, Waikato Clinical School, Hamilton, New Zealand, ⁶University of Otago, Christchurch, New Zealand, ⁷Timaru Medical Specialists Ltd, Timaru, New Zealand, ⁸Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand
Background/Purpose: Analysis of data from several cohort studies of patients with ankylosing spondylitis (AS) /axial spondyloarthritis (AxSpA) have confirmed earlier suggestions that current smokers have…
Abstract Number: 1512 • 2017 ACR/ARHP Annual Meeting
Is Sacroiliac Imaging the All-Decisive Factor in the Diagnosis of Early Axial Spondyloarthritis? Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Zineb Ez-Zaitouni¹, Robert B.M. Landewé², Miranda van Lunteren¹, Pauline Bakker¹, Karen M Fagerli³, Roberta Ramonda⁴, Lennart TH Jacobsson⁵, Désirée van der Heijde⁶ and Floris van Gaalen⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, University of Padova, Padova, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Imaging of the sacroiliac joints plays a pivotal role in the recognition of axSpA. However, interpretation of imaging is challenging and has led to…
Abstract Number: 1547 • 2017 ACR/ARHP Annual Meeting
Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)
Jun Won Park¹, Jin Kyun Park¹, Kichul Shin², Yong-Beom Park³, Eun Bong Lee¹, Yeong Wook Song⁴ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)…
Abstract Number: 2511 • 2017 ACR/ARHP Annual Meeting
Irritable Bowel Syndrome and Its Impact on Patient-Reported Outcomes in Axial Spondyloarthritis: Is It an Overlooked Comorbidity?
Tor Olofsson¹, Elisabeth Mogard¹, Jan Marsal², Mats Geijer³, Lars Erik Kristensen⁴, Elisabet Lindqvist¹ and Johan K Wallman⁵, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences Lund, Gastroenterology, Lund University, Lund, Sweden, ³Department of Radiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ⁴Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁵Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden
Background/Purpose: While inflammatory bowel disease (IBD) is a well-known comorbidity in axial spondyloarthritis (SpA), little is known about functional bowel problems, such as irritable bowel…
Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Maxime Dougados¹, Philip J Mease², Joachim Sieper³, Peter C. Taylor⁴, Natasha de Peyrecave⁵, Tommi Nurminen⁶ and Jürgen Braun⁷, ¹Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Charité University Hospital, Berlin, Germany, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…
Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Victor S. Sloan¹, Anna Sheahan¹, Jeffrey Stark² and Robert Y. Suruki¹, ¹UCB Pharma, Raleigh, NC, ²UCB Pharma, Smyrna, GA
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].